Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 3Melanoma 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Papillomavirus Infections 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Liver Diseases 1Liposarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 40Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 32Papillomavirus Vaccines 24Human Papillomavirus Recombinant Vaccine nonavalent 12Vaccines 11Blood Specimen Collection 10Data Collection 9Colposcopy 9Human Papillomavirus DNA Tests 8Specimen Handling 7Radiotherapy, Intensity-Modulated 7Cisplatin 7Surveys and Questionnaires 6Educational Status 6Early Intervention, Educational 6Carboplatin 6Vaginal Smears 5Vaccines, Synthetic 5Methods 5Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Polymerase Chain Reaction 3Patient Navigation 3Paclitaxel 3Observation 3Mass Screening 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × Adjuvants, Pharmaceutic × Clear all
NCT00693615 2016-09-16

Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

GlaxoSmithKline

Phase 2 Completed
60 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡